Ikena Oncology (NASDAQ:IKNA) Rating Lowered to Hold at Zacks Investment Research

Ikena Oncology (NASDAQ:IKNA – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. They presently have a $7.00 target price on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 25.67% from the company’s previous […]

Related Keywords

Boston ,Massachusetts ,United States ,Blackrock ,Thomson Reuter ,Northern Trust Corp ,Geode Capital Management ,Credit Suisse Group ,Zacks Investment Research ,Blackrock Inc ,Ikena Oncology Inc ,Ikena Oncology Company Profile Get Rating ,Ikena Oncology ,Get Rating ,Investment Research ,Suisse Group ,Street Corp ,Trust Corp ,Capital Management ,Oncology Company Profile ,Nasdaq Ikna ,Vikna ,Medical ,Downgrade ,